Failure pattern · India · 2008–2014
Ranbaxy: an Indian pharma pioneer undone by data-integrity failures
Japan's Daiichi Sankyo bought control of Ranbaxy for about $4.6 billion in 2008. US regulators then banned its plants over data-integrity failures, and Daiichi sold Ranbaxy to Sun Pharma in 2014.
By Shivam Bhandari · Reviewed 31 October 2026 · How we write
by the numbers
- Daiichi Sankyo purchase (2008)
- about $4.6 billion
- US penalties (2013)
- about $500 million
- Sale to Sun Pharma (2014)
- about $4 billion including debt
What happened
Ranbaxy was one of India's first drug companies to build a major presence in the US generic-medicine market. In 2008 Japan's Daiichi Sankyo bought a controlling stake for about $4.6 billion.
Soon after, the US Food and Drug Administration blocked imports from several Ranbaxy plants over manufacturing and data-integrity problems — including falsified test data. In 2013 Ranbaxy pleaded guilty in the US and paid about $500 million in penalties.
In 2014 Daiichi Sankyo sold Ranbaxy to Sun Pharma in an all-share deal valued at about $4 billion including debt. Sun, led by Dilip Shanghvi, spent years fixing the plants.
Timeline
- 2008
Daiichi Sankyo buys control; FDA import bans.
- 2013
Guilty plea and penalties in the US.
- 2014
Sun Pharma deal announced.
what went wrong
- Quality and data-integrity failures.
- Acquirer's due diligence missed the risks.
- Regulatory trust, once lost, is slow to regain.
the lesson
In regulated industries, quality and honest data are the business — a breach can wipe out years of value.
Apply it to your business
- 1Audit quality and data practices before acquiring.
- 2Treat regulatory compliance as core, not overhead.
- 3Build a culture where falsifying data is unthinkable.
Laws at work in this story
Figures are rounded and drawn from public reports, company filings and widely cited coverage at the time. Check the company's latest filings before relying on any number.